In their retrospective analysis, Derangère et al. observed that a previous anti-VEGF therapy decreased anti-EGFR efficacy in KRAS and NRAS wildtype CRC, resulting in shorter PFS [22]. The gene discussed is VEGFA; the disease is colorectal carcinoma.